LONDON – Big data has the power to change the way drugs are accessed, used and regulated, but there are barriers to its implementation – in complying with data protection legislation, engendering trust, understanding the strengths and limitations of datasets and developing analytical methods to reach conclusions that can be transferred through to regulatory decisions.